Revvity Dihydroxyphenylethylamine (Dopamine), 3,4--, 250uCi (9.25MBq)

250 µCi quantities of Dihydroxyphenylethylamine (Dopamine), 3,4-[Ring-2,5,6-³H]-, are available for your research. Dihydroxyphenylethylamine binds dopamine receptors, a class of GPCRs in the central nervous system. Dopamine receptors are implicated in motivation, pleasure, cognition, memory, and learning and are potential drug targets for schizophrenia, Parkinsons disease, and a variety of other psychiatric and neurological conditions.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET673:

1. Schmitt, M., Dehay, B., Bezard, E. and Garcia-Ladona, F. J. (2016), Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line. Synapse, 70: 71–86.
2. A.L. Auclair, J.C. Martel, M.B. Assié, L. Bardin, P. Heusler, D. Cussac, M. Marien, A. Newman-Tancredi, J.A. OConnor, R. Depoortère, Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety, In Neuropharmacology, Volume 70, 2013, Pages 338-347.